TSMHT
AMED

Thurston Springer Miller Herd & Titak’s Amedisys AMED Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37
Closed -$3.41K – 1547
2024
Q1 		$3.41K Buy
+37
New +$3.47K ﹤0.01% 133

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's AMED Position: Q2 2024 in Review

Thurston Springer Miller Herd & Titak sold out of Amedisys (AMED) in Q2 2024, closing a stake of 37 shares — an estimated $3.41K sold.

Thurston Springer Miller Herd & Titak first reported a position in AMED in Q1 2024 and held it in 1 quarter. The position peaked at $3.41K in Q1 2024. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2024.

  • Thurston Springer Miller Herd & Titak reported no remaining Amedisys position as of Q2 2024 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 37 Amedisys shares in Q2 2024, an estimated $3.41K.
  • Thurston Springer Miller Herd & Titak first reported a position in Amedisys in Q1 2024 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Amedisys position peaked at $3.41K in Q1 2024.
  • 288 funds tracked by Wall St. Rank held Amedisys as of Q2 2024.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2024, filed 5 Jul 2024.